Tumour size determines both recurrence-free survival and disease-specific survival after surgical treatment for thymoma

Meinoshin Okumura, Ichiro Yoshino, Motoki Yano, Shun Ichi Watanabe, Masahiro Tsuboi, Kazuo Yoshida, Hiroshi Date, Kohei Yokoi, Jun Nakajima, Shinichi Toyooka, Hisao Asamura, Etsuo Miyaoka

Research output: Contribution to journalArticle

Abstract

OBJECTIVES: The tumour, node and the metastasis (TNM) staging system for thymic epithelial tumours was adopted by the Union for International Cancer Control (UICC) in 2016. Although the T factor is defined by the invasive nature of a thymoma, tumour size is not considered. The aim of this study was to examine the clinical importance of tumour size using a nationwide retrospective database of cases treated from 1991 to 2010 compiled by the Japanese Association for Research of the Thymus. METHODS: Tumour size was evaluated by the maximum diameter shown by computed tomography imaging prior to resection. Tumour size was available for 2083 thymoma patients undergoing upfront surgical treatment. The tumour size ranged from 0.6 to 19.4 cm (mean 5.1 cm, median 4.9 cm). Harrell's C-index was adopted to determine the cut-off value of the tumour size in 0.5-cm increments. RESULTS: The highest C-index value (0.7760) was obtained in terms of recurrence-free survival after the complete resection when the cut-off value was set at 5.0 cm. The 10-year recurrence-free survival rate was 93.8% in patients with a tumour ≤5.0 cm and 84.3% in patients with a tumour >5.0 cm (P < 0.0001). The highest C-index value (0.8885) in terms of disease-specific survival was obtained when the cut-off value was set at 8.0 cm. The 10-year disease-specific survival rate was 98.8% in patients with a tumour <8.0 cm and 90.1% in those with a tumour ≥8.0 cm (P < 0.0001). The Cox's proportional hazard model analysis showed that the tumour size and the TNM-based pathological stage were independent factors to determine both recurrence-free survival and disease-specific survival. CONCLUSIONS: Tumour size is an important prognostic factor and should be considered when determining the treatment strategy for thymoma patients.

Original languageEnglish
Pages (from-to)174-181
Number of pages8
JournalEuropean journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
Volume56
Issue number1
DOIs
Publication statusPublished - Jul 1 2019

Fingerprint

Thymoma
Disease-Free Survival
Recurrence
Survival
Neoplasms
Therapeutics
Survival Rate
Neoplasm Metastasis
Proportional Hazards Models
Thymus Gland

Keywords

  • Prognostic factor
  • Thymic epithelial tumour
  • Tumor node and metastasis (TNM) staging

ASJC Scopus subject areas

  • Surgery
  • Pulmonary and Respiratory Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Tumour size determines both recurrence-free survival and disease-specific survival after surgical treatment for thymoma. / Okumura, Meinoshin; Yoshino, Ichiro; Yano, Motoki; Watanabe, Shun Ichi; Tsuboi, Masahiro; Yoshida, Kazuo; Date, Hiroshi; Yokoi, Kohei; Nakajima, Jun; Toyooka, Shinichi; Asamura, Hisao; Miyaoka, Etsuo.

In: European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery, Vol. 56, No. 1, 01.07.2019, p. 174-181.

Research output: Contribution to journalArticle

Okumura, Meinoshin ; Yoshino, Ichiro ; Yano, Motoki ; Watanabe, Shun Ichi ; Tsuboi, Masahiro ; Yoshida, Kazuo ; Date, Hiroshi ; Yokoi, Kohei ; Nakajima, Jun ; Toyooka, Shinichi ; Asamura, Hisao ; Miyaoka, Etsuo. / Tumour size determines both recurrence-free survival and disease-specific survival after surgical treatment for thymoma. In: European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery. 2019 ; Vol. 56, No. 1. pp. 174-181.
@article{55737bfe15d04c779d10721b421e000f,
title = "Tumour size determines both recurrence-free survival and disease-specific survival after surgical treatment for thymoma",
abstract = "OBJECTIVES: The tumour, node and the metastasis (TNM) staging system for thymic epithelial tumours was adopted by the Union for International Cancer Control (UICC) in 2016. Although the T factor is defined by the invasive nature of a thymoma, tumour size is not considered. The aim of this study was to examine the clinical importance of tumour size using a nationwide retrospective database of cases treated from 1991 to 2010 compiled by the Japanese Association for Research of the Thymus. METHODS: Tumour size was evaluated by the maximum diameter shown by computed tomography imaging prior to resection. Tumour size was available for 2083 thymoma patients undergoing upfront surgical treatment. The tumour size ranged from 0.6 to 19.4 cm (mean 5.1 cm, median 4.9 cm). Harrell's C-index was adopted to determine the cut-off value of the tumour size in 0.5-cm increments. RESULTS: The highest C-index value (0.7760) was obtained in terms of recurrence-free survival after the complete resection when the cut-off value was set at 5.0 cm. The 10-year recurrence-free survival rate was 93.8{\%} in patients with a tumour ≤5.0 cm and 84.3{\%} in patients with a tumour >5.0 cm (P < 0.0001). The highest C-index value (0.8885) in terms of disease-specific survival was obtained when the cut-off value was set at 8.0 cm. The 10-year disease-specific survival rate was 98.8{\%} in patients with a tumour <8.0 cm and 90.1{\%} in those with a tumour ≥8.0 cm (P < 0.0001). The Cox's proportional hazard model analysis showed that the tumour size and the TNM-based pathological stage were independent factors to determine both recurrence-free survival and disease-specific survival. CONCLUSIONS: Tumour size is an important prognostic factor and should be considered when determining the treatment strategy for thymoma patients.",
keywords = "Prognostic factor, Thymic epithelial tumour, Tumor node and metastasis (TNM) staging",
author = "Meinoshin Okumura and Ichiro Yoshino and Motoki Yano and Watanabe, {Shun Ichi} and Masahiro Tsuboi and Kazuo Yoshida and Hiroshi Date and Kohei Yokoi and Jun Nakajima and Shinichi Toyooka and Hisao Asamura and Etsuo Miyaoka",
year = "2019",
month = "7",
day = "1",
doi = "10.1093/ejcts/ezz001",
language = "English",
volume = "56",
pages = "174--181",
journal = "European Journal of Cardio-thoracic Surgery",
issn = "1010-7940",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Tumour size determines both recurrence-free survival and disease-specific survival after surgical treatment for thymoma

AU - Okumura, Meinoshin

AU - Yoshino, Ichiro

AU - Yano, Motoki

AU - Watanabe, Shun Ichi

AU - Tsuboi, Masahiro

AU - Yoshida, Kazuo

AU - Date, Hiroshi

AU - Yokoi, Kohei

AU - Nakajima, Jun

AU - Toyooka, Shinichi

AU - Asamura, Hisao

AU - Miyaoka, Etsuo

PY - 2019/7/1

Y1 - 2019/7/1

N2 - OBJECTIVES: The tumour, node and the metastasis (TNM) staging system for thymic epithelial tumours was adopted by the Union for International Cancer Control (UICC) in 2016. Although the T factor is defined by the invasive nature of a thymoma, tumour size is not considered. The aim of this study was to examine the clinical importance of tumour size using a nationwide retrospective database of cases treated from 1991 to 2010 compiled by the Japanese Association for Research of the Thymus. METHODS: Tumour size was evaluated by the maximum diameter shown by computed tomography imaging prior to resection. Tumour size was available for 2083 thymoma patients undergoing upfront surgical treatment. The tumour size ranged from 0.6 to 19.4 cm (mean 5.1 cm, median 4.9 cm). Harrell's C-index was adopted to determine the cut-off value of the tumour size in 0.5-cm increments. RESULTS: The highest C-index value (0.7760) was obtained in terms of recurrence-free survival after the complete resection when the cut-off value was set at 5.0 cm. The 10-year recurrence-free survival rate was 93.8% in patients with a tumour ≤5.0 cm and 84.3% in patients with a tumour >5.0 cm (P < 0.0001). The highest C-index value (0.8885) in terms of disease-specific survival was obtained when the cut-off value was set at 8.0 cm. The 10-year disease-specific survival rate was 98.8% in patients with a tumour <8.0 cm and 90.1% in those with a tumour ≥8.0 cm (P < 0.0001). The Cox's proportional hazard model analysis showed that the tumour size and the TNM-based pathological stage were independent factors to determine both recurrence-free survival and disease-specific survival. CONCLUSIONS: Tumour size is an important prognostic factor and should be considered when determining the treatment strategy for thymoma patients.

AB - OBJECTIVES: The tumour, node and the metastasis (TNM) staging system for thymic epithelial tumours was adopted by the Union for International Cancer Control (UICC) in 2016. Although the T factor is defined by the invasive nature of a thymoma, tumour size is not considered. The aim of this study was to examine the clinical importance of tumour size using a nationwide retrospective database of cases treated from 1991 to 2010 compiled by the Japanese Association for Research of the Thymus. METHODS: Tumour size was evaluated by the maximum diameter shown by computed tomography imaging prior to resection. Tumour size was available for 2083 thymoma patients undergoing upfront surgical treatment. The tumour size ranged from 0.6 to 19.4 cm (mean 5.1 cm, median 4.9 cm). Harrell's C-index was adopted to determine the cut-off value of the tumour size in 0.5-cm increments. RESULTS: The highest C-index value (0.7760) was obtained in terms of recurrence-free survival after the complete resection when the cut-off value was set at 5.0 cm. The 10-year recurrence-free survival rate was 93.8% in patients with a tumour ≤5.0 cm and 84.3% in patients with a tumour >5.0 cm (P < 0.0001). The highest C-index value (0.8885) in terms of disease-specific survival was obtained when the cut-off value was set at 8.0 cm. The 10-year disease-specific survival rate was 98.8% in patients with a tumour <8.0 cm and 90.1% in those with a tumour ≥8.0 cm (P < 0.0001). The Cox's proportional hazard model analysis showed that the tumour size and the TNM-based pathological stage were independent factors to determine both recurrence-free survival and disease-specific survival. CONCLUSIONS: Tumour size is an important prognostic factor and should be considered when determining the treatment strategy for thymoma patients.

KW - Prognostic factor

KW - Thymic epithelial tumour

KW - Tumor node and metastasis (TNM) staging

UR - http://www.scopus.com/inward/record.url?scp=85068418913&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068418913&partnerID=8YFLogxK

U2 - 10.1093/ejcts/ezz001

DO - 10.1093/ejcts/ezz001

M3 - Article

VL - 56

SP - 174

EP - 181

JO - European Journal of Cardio-thoracic Surgery

JF - European Journal of Cardio-thoracic Surgery

SN - 1010-7940

IS - 1

ER -